Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies
This study revealed gaps in treatment priorities; patients valued quality of life and AE management, while HCPs focused on efficacy and delaying progression. There is a significant need to educate HCPs and patients on the impact of shared decision-making when considering novel treatments for RRMM.
Authors
- Solène Clavreul (ORCID: https://orcid.org/0000-0001-5384-8425)
- Anna Sato (ORCID: https://orcid.org/0000-0001-7259-3069)
- Sikander Ailawadhi (ORCID: https://orcid.org/0000-0002-8377-8111)
- Erinn Hoag Goldman
- Yvonne A. Efebera (ORCID: https://orcid.org/0000-0002-4163-8823)
- Yelak Biru
- James J. Farrell (ORCID: https://orcid.org/0000-0002-5665-4519)
- Maria J. de Miguel (ORCID: https://orcid.org/0000-0002-9366-8602)
- Rakesh Popat (ORCID: https://orcid.org/0000-0001-6553-4618)
- Maximilian Merz (ORCID: https://orcid.org/0000-0002-2805-5973)
- Nicolas Cormier (ORCID: https://orcid.org/0009-0007-5526-6104)
- Jack L. Watkins
- Cathy Zeanah
Institutions
- OhioHealth (US)
- Memorial Sloan Kettering Cancer Center (US)
- University College London Hospitals NHS Foundation Trust (GB)
- Pfizer (United States) (US)
- WinnMed (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- National Institute for Health and Care Research (GB)
- European Federation of Allergy and Airways Diseases Patients Associations (BE)
- Clinica Universidad de Navarra (ES)
- Mayo Clinic in Florida (US)
- International Myeloma Foundation (US)
- Pfizer (Ireland) (IE)
- University College London (GB)
Publication Details
- Journal
- Patient Preference and Adherence
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ppa.s496106
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Multiple Myeloma Research Foundation
- Pfizer